IL114343A0 - Use of IGF-I in the prevention of diabetes - Google Patents

Use of IGF-I in the prevention of diabetes

Info

Publication number
IL114343A0
IL114343A0 IL11434395A IL11434395A IL114343A0 IL 114343 A0 IL114343 A0 IL 114343A0 IL 11434395 A IL11434395 A IL 11434395A IL 11434395 A IL11434395 A IL 11434395A IL 114343 A0 IL114343 A0 IL 114343A0
Authority
IL
Israel
Prior art keywords
diabetes
igf
subject
high risk
prevention
Prior art date
Application number
IL11434395A
Other languages
English (en)
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of IL114343A0 publication Critical patent/IL114343A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IL11434395A 1994-07-04 1995-06-26 Use of IGF-I in the prevention of diabetes IL114343A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402370A SE9402370D0 (sv) 1994-07-04 1994-07-04 Use of IGF-I

Publications (1)

Publication Number Publication Date
IL114343A0 true IL114343A0 (en) 1995-10-31

Family

ID=20394633

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11434395A IL114343A0 (en) 1994-07-04 1995-06-26 Use of IGF-I in the prevention of diabetes

Country Status (10)

Country Link
US (2) US6342227B1 (de)
EP (1) EP0759776B1 (de)
JP (1) JPH10502367A (de)
AT (1) ATE223729T1 (de)
AU (1) AU689922B2 (de)
CA (1) CA2194403A1 (de)
DE (1) DE69528168T2 (de)
IL (1) IL114343A0 (de)
SE (1) SE9402370D0 (de)
WO (1) WO1996001124A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
ATE251466T1 (de) 1999-04-08 2003-10-15 Genentech Inc Zusammensetzung auf basis gegensätzlich geladener polypeptide
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
JP4489352B2 (ja) 2001-02-09 2010-06-23 ジェネンテック, インコーポレイテッド Igf−1の結晶化
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP2453019A4 (de) 2009-07-10 2013-04-17 Univ Barcelona Autonoma Gentherapiezusammensetzungen zur prävention und/oder behandlung von autoimmunerkrankungen
US10799564B1 (en) * 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0561137B1 (de) 1983-04-25 2002-07-03 Chiron Corporation Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US4963665A (en) 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1

Also Published As

Publication number Publication date
ATE223729T1 (de) 2002-09-15
AU2940795A (en) 1996-01-25
AU689922B2 (en) 1998-04-09
EP0759776B1 (de) 2002-09-11
EP0759776A1 (de) 1997-03-05
DE69528168D1 (de) 2002-10-17
DE69528168T2 (de) 2003-01-09
WO1996001124A1 (en) 1996-01-18
JPH10502367A (ja) 1998-03-03
US6342227B1 (en) 2002-01-29
CA2194403A1 (en) 1996-01-18
SE9402370D0 (sv) 1994-07-04
US20020132772A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
ES2001996A6 (es) Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad.
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
AU7320387A (en) Prevention of outgassing in polyvinylsiloxane elastomers by the use of finely divided platinum black
AU6898487A (en) Haloarylnitrile degrading gene, its use, and cells containing the same
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
IL114343A0 (en) Use of IGF-I in the prevention of diabetes
AU3542684A (en) Glycemia regulating implant
AU1924795A (en) Treatment and/or prevention of type i diabetes mellitus with gamma interferon administration
IT8022925A0 (it) Composizioni di gomma siliconica ad un componente, vulcanizzabili atemperatura ambiente e stabili all'immagazzinamento.
DE3170587D1 (en) The use of peptides as medicaments and certain novel peptides
AU1021688A (en) Orthopedic foot splint with swivel and stop
AU4649485A (en) Battery saver
HU910968D0 (en) New retinoids
AU6299596A (en) Prevention of a disease having the characteristics of diabetes
ES8403884A1 (es) Un procedimiento para la preparacion de nuevos 2,3-diaril-5-halotiofenos.
AU574978B2 (en) Method for treatment of antidiuresis employing serine derivatives
EP1123100A4 (de) Gedächnissverbesserung durch verabreichung von delta-5-androsten-3-beta-ol-7,17-dion und 3-beta-estern desselben
USD287881S (en) Incontinence pad
ZA851927B (en) Pharmaceutical composition containing 9alpha,11beta-dichloro-16alpha-methyl-21-oxycarbonyldicyclohexylmethyloxy preggna-1,4-diene-3,20-dione
AU8759782A (en) Human proinsulin and human c-peptide and human insulin formulations
ATE36333T1 (de) Hydantoin enthaltende therapeutische mittel.
RO92445B1 (ro) Unguent medicamentos cu actiune antiinflamatoare, cicatrizanta si epitelizanta
Hee Pancreatic secretions in the growing pig
EP0278715A3 (de) Verwendung von menschlichem Gamma-Interferon für die Behandlung von Basalzell-Karzinomen
Haya On the Concept of “Fall” in Early Buddhism